FDA starts review of Argenx drug in rare disease CIDP

Submitted by admin on February 20, 2024 - 11:01am

Source:

Pharmaphorum

News Tags:

Argenx

Vygart Hytrulo

CIDP

FDA

Headline:

FDA starts review of Argenx drug in rare disease CIDP

snippet:

The US FDA has said it plans to deliver a decision in June on the use of Argenx’ Vyvgart Hytrulo in chronic inflammatory demyelinating polyneuropathy (CIDP), as the company tries to turn around a run of bad news with the drug.

Search form

You are here

FDA starts review of Argenx drug in rare disease CIDP

FDA starts review of Argenx drug in rare disease CIDP